Hemostatic devices and methods of use
An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.
1. A surgical system comprising:
an anchorage device configured to secure an implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising collagen having a first hemostatic agent homogenously distributed therein, the anchorage device comprising a polymer having a second hemostatic agent dispersed therein, the polymer having the second hemostatic agent dispersed therein directly applied to at least one of the first piece and the second piece.
2. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed defines a coating that covers the first piece without covering the second piece.
3. The surgical system recited in claim 1 , wherein the first hemostatic agent does not include collagen, the second hemostatic agent does not include collagen, or both.
4. The surgical system recited in claim 1 , wherein the first hemostatic agent is tranexamic acid, the second hemostatic agent is tranexamic acid, or both.
5. The surgical system recited in claim 1 , further comprising the implantable medical device, the implantable medical device being selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices.
6. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed therein completely covers the first piece and does not cover the second piece.
7. The surgical system recited in claim 1 , wherein the substrate is a mesh substrate.
8. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed therein defines a first coating, the second piece comprising a second coating that covers at least a portion of the second piece, the first coating being different from the second coating.
9. The surgical system recited in claim 8 , wherein the polymer and the second hemostatic agent are each directly applied to the first piece.
10. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed therein covers the first piece and the second piece.
11. The surgical system recited in claim 1 , wherein the first hemostatic agent comprises tranexamic acid, the second hemostatic agent comprises tranexamic acid, or both.
12. The surgical system recited in claim 1 , wherein the polymer is poly (D,L-lactide-co-glycolide).
13. The surgical system recited in claim 1 , wherein the polymer is a tyrosine-derived polyarylate.
14. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed therein is a first polymer and covers the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece, the second polymer having a combination of rifampin and minocycline dispersed therein.
15. The surgical system recited in claim 14 , wherein:
the second hemostatic agent is tranexamic acid;
the first polymer is poly (D,L-lactide-co-glycolide); and
the second polymer is a tyrosine-derived polyarylate.
16. The surgical system recited in claim 1 , wherein the polymer having the second hemostatic agent dispersed therein is a first polymer and covers the first piece, the second piece comprising a second polymer that covers the second piece, the second polymer having a combination of rifampin and minocycline dispersed therein.
17. The surgical system recited in claim 16 , wherein the second polymer having the combination of rifampin and minocycline dispersed therein is directly applied to the second piece.
18. The surgical system recited in claim 1 , wherein the collagen comprises hydrolyzed collagen.
19. A surgical system comprising:
an implantable medical device selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices; and
an anchorage device configured to secure the implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising hydrolyzed collagen having a hemostatic agent homogenously distributed therein, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece,
wherein the first polymer is poly (D,L-lactide-co-glycolide) and has tranexamic acid dispersed therein, the first polymer having tranexamic acid dispersed therein directly applied to the first piece, and
wherein the second polymer is a tyrosine-derived polyarylate and has a combination of rifampin and minocycline dispersed therein.
20. A surgical system consisting of:
an implantable medical device selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices; and
an anchorage device configured to secure the implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising collagen having a hemostatic agent homogenously distributed therein, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece,
wherein the first polymer is a tyrosine-derived polyarylate and has a combination of rifampin and minocycline dispersed therein, and
wherein the second polymer is poly (D,L-lactide-co-glycolide) and has tranexamic acid dispersed therein, the second polymer having tranexamic acid dispersed therein directly applied to the second piece.